Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Keros Therapeutics Inc KROS.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.25. The mean expectation of twelve analysts for the quarter was for a loss of $1.13 per share. Wall Street expected results to range from $-1.35 to -71 cents per share.

• Revenue rose 49,002.7% to $18.17 million from a year ago; analysts expected $2.77 million.

• Keros Therapeutics Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $30.7 million.

• Keros Therapeutics Inc shares had risen by 7.8% this quarter and lost 9.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Keros Therapeutics Inc is $25.00, about 42.4% above its last closing price of $14.39

This summary was machine generated from LSEG data August 6 at 08:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)